item1.txt
As of March 31, 2018, the Company had no assets or liabilities measured and recorded at fair value on a recurring basis using Level 3 inputs.
The Company used the income approach in accordance with the excess-earnings method to estimate the fair values of customer relationships, backlog and trademarks equal to the present value of the after-tax cash flows attributable to each intangible asset.
During the three months ended March 31, 2018, revenue and net loss from 4titude recognized in the Company’s results of operations were $4.3 million and less than $0.1 million, respectively.
During the six months ended March 31, 2018, revenue and net loss from 4titude recognized in the Company’s results of operations were $7.8 million and $1.2 million, respectively.
During the six months ended March 31, 2018, the net loss included non-recurring charges of $1.2 million related to the step-up in value of the acquired inventories.
During the three and six months ended March 31, 2018, the net loss included recurring charges of $1.0 million and $2.1 million, respectively, related to amortization expense of acquired intangible assets.
During the three months ended March 31, 2018, revenue and net loss from PBMMI recognized in the Company’s results of operations were $2.5 million and less than $0.1 million, respectively.
During the six months ended March 31, 2018, revenue and net loss from PBMMI recognized in the Company’s results of operations were $4.8 million and $0.1 million, respectively.
During the three and six months ended March 31, 2018, the net loss included recurring charges of $0.4 million and $0.8 million, respectively, related to amortization expense of acquired intangible assets.
The Company recorded a liability of $0.7 million in the purchase price allocation that represented a preacquisition contingency incurred on the acquisition date.
Please refer to Note 6, "Goodwill and Intangible Assets" to the Company's consolidated financial statements included in the 2017 Annual Report on Form 10-K for further information on the goodwill impairment testing performed during fiscal year 2017.
During the six months ended March 31, 2018, the Company recorded a goodwill increase of $41.6 million primarily related to the acquisition of 4titude which represented the excess of the consideration transferred over the fair value of the net assets acquired.
Amortization expense for intangible assets was $11.1 million and $8.4 million, respectively, during the six months ended March 31, 2018 and 2017.
During the three months ended March 31, 2018 and 2017, the Company recorded income of $1.4 million and $2.8 million, respectively, representing its proportionate share of UCI’s earnings.
During the six months ended March 31, 2018 and 2017, the Company recorded income of $3.6 million and $5.2 million, respectively, representing its proportionate share of UCI’s earnings.
Management fee payments received by the Company from UCI were $0.3 million and $0.2 million during the three months ended March 31, 2018 and 2017.
Management fee payments received by the Company from UCI were $0.5 million during each of the six months ended March 31, 2018 and 2017.
The Company records commitment fees and other costs directly associated with obtaining line of credit financing as deferred financing costs which are presented within "Other assets" in the accompanying unaudited Consolidated Balance Sheets.
The Company incurred additional deferred financing costs of $0.4 million during the six months ended March 31, 2018.
The Company would be required to redeem the term loan at the principal amount then outstanding upon occurrence of certain events, including (i) net proceeds received from the sale or other disposition of the Company’s or guarantor’ assets, subject to certain limitations, (ii) casualty and condemnation proceeds received by the Company or the guarantor, subject to certain exceptions, (iii) net proceeds received by the Company or the guarantor from the issuance of debt or disqualified capital stock after October 4, 2017.
The Company records commitment fees and other costs directly associated with obtaining term loan financing as deferred financing costs which are presented as a reduction of the term loan principal balance in the accompanying unaudited Consolidated Balance Sheets.
During the six months ended March 31, 2018, the Company incurred aggregate interest expense of $4.2 million in connection with the term loan borrowings, which included $0.2 million of deferred financing costs amortization.
The Company recorded an income tax benefit of $43.9 million and $41.0 million, respectively, during the three and six months ended March 31, 2018.
At March 31, 2018 and September 30, 2017, the Company had cumulative capitalized direct costs of $5.0 million and $4.7 million, respectively, associated with the development of software for its internal use which are included within "Property, plant and equipment, net" in the accompanying unaudited Consolidated Balance Sheets.
During the six months ended March 31, 2018, the Company capitalized direct costs of $0.3 million associated with development of software for its internal use.
During the six months ended March 31, 2018 and 2017, the Company granted 34,926 and 42,560 units, respectively, to the members of the Company's Board of Directors, including 26,539 and 28,065 units, respectively, that were compensation-related.
Compensation-related units granted during the six months ended March 31, 2018 and 2017 are subject to a one-year vesting period starting from the grant date.
The units granted during the six months ended March 31, 2018 will vest on the date which is one day before the Company's 2019 Annual Meeting of Stockholders.
The units granted during the six months ended March 31, 2017 vested on January 30, 2018, which was one day before the Company's 2018 Annual Meeting of Stockholders.
During the six months ended March 31, 2018 and 2017, the Company granted 7,130 and 13,065 units, respectively, related to such deferred annual restricted share awards, as well as 1,257 and 1,430 units, respectively, related to deferred quarterly dividends.
Annual restricted share awards granted during the six months ended March 31, 2018 and 2017 are subject to a one-year vesting period starting from the grant date.
The amount of units granted during the six months ended March 31, 2018 and 2017 related to deferred quarterly dividends was equal to the value of cash dividends that would be paid on the number of total deferred shares based on the closing price of the Company’s stock on the dividend record date.
The weighted average grant date fair value of restricted stock units granted during the three months ended March 31, 2018 and 2017 was $25.41 and $20.76, respectively.
The weighted average grant date fair value of restricted stock units granted during the six months ended March 31, 2018 and 2017 was $33.61 and $14.32, respectively.
The fair value of restricted stock units vested during the three months ended March 31, 2018 and 2017 was $0.1 million and $0.6 million, respectively.
The fair value of restricted stock units vested during the six months ended March 31, 2018 and 2017 was $19.1 million and $11.9 million, respectively.
During the six months ended March 31, 2018 and 2017, the Company remitted $6.3 million and $3.8 million, respectively, for withholding taxes on vested restricted stock units, of which $0.1 million was paid by the Company during the six months ended March 31, 2017.
There were no taxes on vested restricted stock units paid by the Company during the six months ended March 31, 2018.
During the six months ended March 31, 2018 and 2017, the Company received $6.3 million and $3.7 million, respectively, in cash proceeds from employees to satisfy their tax obligations as a result of share issuances.
As of March 31, 2018, the unrecognized compensation cost related to restricted stock units that are expected to vest is $30.1 million and will be recognized over an estimated weighted average service period of approximately 1.8 years.
The Company maintains an Employee Stock Purchase Plan that allows its employees to purchase shares of common stock at a price equal to 85% of the fair market value of the Company’s stock at the beginning or the end of the semi-annual period, whichever is lower.
The Company had one customer that accounted for 10% or more of its consolidated revenue, at 12% and 10%, respectively, during the three months ended March 31, 2018 and 2017.
The Company had one customer that accounted for 10% or more of its consolidated revenue, at 12% and 11%, respectively, during the six months ended March 31, 2018 and 2017.
The Company has non-cancellable contracts and purchase orders for inventory of $163.7 million and $122.0 million, respectively, at March 31, 2018 and September 30, 2017.
The Company has not presented a purchase price allocation related to fair values of assets acquired and liabilities assumed, nor pro-forma information summary for its consolidated results of operations for the fiscal year ended September 30, 2017 and 2016 as if the acquisition occurred on October 1, 2015 because the initial accounting for the acquisition was incomplete on the financial statements issuance date.
The Company has not presented a purchase price allocation related to fair values of assets acquired and liabilities assumed, nor pro-forma information summary for its consolidated results of operations for the fiscal year ended September 30, 2017 and 2016 as if the acquisition occurred on October 1, 2015 because the initial accounting for the acquisition was incomplete on the financial statements issuance date.


item2.txt
Results of Operations- Revenue for the three months ended March 31, 2018 increased to $207.3 million, or by 22%, as compared to the corresponding period of the prior fiscal year.
Net income was $67.0 million for the three months ended March 31, 2018 as compared to $14.0 million for the corresponding period of the prior fiscal year.
These increases were partially offset by higher non-operating expenses of $1.9 million compared to the corresponding period of the prior fiscal year, primarily related to interest expense on the term loan and lower net income from equity method investments of $1.4 million.
Results of Operations- Revenue for the six months ended March 31, 2018 increased to $396.6 million, or by 20%, as compared to the corresponding period of the prior fiscal year.
Gross margin was 40.2% for the six months ended March 31, 2018 as compared to 36.9% for the six months ended March 31, 2017, which resulted in an increase in gross profit of $38.0 million.
Operating expenses were $114.8 million during the six months ended March 31, 2018 as compared to $93.5 million during the six months ended March 31 2017, an increase of $21.3 million.
Operating income was $44.7 million during the six months ended March 31, 2018 as compared to $28.0 million for the corresponding period of the prior fiscal year.
Net income was $83.5 million for the six months ended March 31, 2018 as compared to $27.9 million for the corresponding period of the prior fiscal year.
These increases were partially offset by higher non-operating expenses of $7.2 million compared to the corresponding period of the prior fiscal year, primarily related to increased interest expense of $4.2 million mainly due to the term loan, higher foreign exchanges losses of $1.5 million and the impact of a $1.8 million gain recorded on the settlement of our investment in Biocision during the six months ended March 31, 2017.
from operating activities during the six months ended March 31, 2018 were comprised primarily of earnings of $57.6 million, including net income of $83.5 million and the impact of non-cash related charges of $25.9 million, partially offset by uses of cash of $34.2 million related to the changes in our operating assets and liabilities, net of acquisitions.
We reported revenue of $207.3 million for the three months ended March 31, 2018, compared to $169.3 million for the corresponding period of the prior fiscal year, an increase of $37.9 million, or 22%.
We reported revenue of $396.6 million for the six months ended March 31, 2018, compared to $329.3 million for the corresponding period of the prior fiscal year, an increase of $67.3 million, or 20%.
The impact of changes in foreign currency exchange rates favorably affected revenue by $2.6 million and $5.0 million, respectively, during the three and six months ended March 31, 2018 when compared to the corresponding periods of the prior fiscal year.
Our Brooks Semiconductor Solutions Group segment reported revenue of $158.7 million for the three months ended March 31, 2018 compared to $134.7 million for the corresponding period of the prior fiscal year, an increase of $24.1 million, or 18%.
For the six months ended March 31, 2018, our Brooks Semiconductor Solutions Group segment reported revenue of $300.6 million compared to $261.3 million for the corresponding period of the prior fiscal year, an increase of $39.3 million, or 15%.
Our Brooks Life Sciences segment reported revenue of $48.5 million for the three months ended March 31, 2018 compared to $34.7 million for the corresponding period of the prior fiscal year.
Our Brooks Life Sciences segment reported revenue of $96.0 million for the six months ended March 31, 2018 compared to $68.0 million for the corresponding period of the prior fiscal year.
Brooks’ Life Sciences internal revenue growth was favorably affected by foreign currency exchange rates which increased revenue by $1.2 million and $1.7 million, respectively, during the three and six months ended March 31, 2018, as compared to the corresponding periods of the prior fiscal year.
Revenue generated outside the United States amounted to $123.8 million, or 60% of total revenue, for the three months ended March 31, 2018 compared to $119.6 million, or 71% of total revenue, for the corresponding period of the prior fiscal year.
Revenue generated outside the United States amounted to $240.9 million, or 61% of total revenue, for the six months ended March 31, 2018 compared to $226.4 million, or 69% of total revenue, for the corresponding period of the prior fiscal year.
We reported gross margins of 40.6% for the three months ended March 31, 2018 compared to 38.1% for the corresponding period of the prior fiscal year.
We reported gross margins of 40.2% for the six months ended March 31, 2018 compared to 36.9% for the corresponding period of the prior fiscal year.
Cost of revenue for the three and six months ended March 31, 2018 included $1.0 million and $1.9 million, respectively, of charges for amortization related to completed technology as compared to $1.1 million and $2.1 million, respectively, incurred during the corresponding periods of the prior fiscal year.
Cost of revenue for the six months ended March 31, 2018 also included $1.2 million of charges related to the sale of inventories obtained in acquisitions to which a step-up in value was applied in purchase accounting.
Excluding the purchasing accounting impact and the amortization of completed technology, margins expanded 2.2 percentage points and 3.3 percentage points, respectively, during the three and six months ended March 31, 2018 as compared to the corresponding periods of the prior fiscal year.
Our Brooks Semiconductor Solutions Group segment reported gross margins of 41.1% for the three months ended March 31, 2018 as compared to 38.1% for the corresponding period of the prior fiscal year.
Our Brooks Semiconductor Solutions Group segment reported gross margins of 41.5% for the six months ended March 31, 2018 as compared to 37.0% for the corresponding period of the prior fiscal year.
Cost of revenue for the three and six months ended March 31, 2018 included $0.6 million and $1.1 million, respectively, of charges for amortization related to completed technology as compared to $0.6 million and $1.3 
The three and six months ended March 31, 2017 each included $0.1 million of charges related to the sale of inventories obtained in acquisitions to which a step-up in value was applied in purchase accounting.
Excluding the purchase accounting impact and the amortization of completed technology, margins expanded 2.8 percentage points and 4.3 percentage points, respectively, during the three and six months ended March 31, 2018 as compared to the corresponding periods of the prior fiscal year.
Our Brooks Life Sciences segment reported gross margins of 39.0% for the three months ended March 31, 2018 as compared to 38.1% for the corresponding period of the prior fiscal year.
Our Brooks Life Sciences segment reported gross margins of 36.1% for the six months ended March 31, 2018 as compared to 36.3% for the corresponding period of the prior fiscal year.
Cost of revenue for the three and six months ended March 31, 2018 included $0.4 million and $0.8 million, respectively, of charges for amortization related to completed technology as compared to $0.4 million and $0.8 million, respectively, incurred during the corresponding periods of the prior fiscal year.
Cost of revenue for the six months ended March 31, 2018 also included $1.2 million of charges related to the sale of inventories obtained in acquisitions to which a step-up in value was applied in purchase accounting.
Excluding the purchasing accounting impact and the amortization of completed technology, margins decreased 0.2 percentage points for the three months ended March 31, 2018 and expanded 0.2 percentage points for the six months ended March 31, 2018, as compared to the corresponding periods of the prior fiscal year.
Research and development expenses were $13.1 million and $26.3 million, respectively, during the three and six months ended March 31, 2018 as compared to $11.3 million and $22.2 million, respectively, during the corresponding periods of the prior fiscal year.
Amortization expense related primarily to customer relationships was $4.6 million and $9.2 million, respectively, during the three and six months ended March 31, 2018 as compared to $3.3 million and $6.4 million, respectively, during the corresponding periods of the prior fiscal year.
During each of the three month periods ended March 31, 2018 and 2017, we recorded other expenses, net, of $0.3 million.
The tax benefit for the six months ended March 31, 2018 included $0.7 million of tax benefits related to the re-measurement of net U.S. deferred tax liabilities to account for the reduced 21 percent statutory federal income tax rate.
During the six months ended March 31, 2017, we incurred losses of $0.5 million from our investment in BioCision which was settled during the first quarter of fiscal year 2017 as a part of the non-cash consideration for the acquisition of Cool Lab in November 2016.
The increase in cash and cash equivalents and marketable securities of $140.9 million was primarily attributable to cash inflows of $197.6 million related to proceeds from the term loan and cash inflows of $23.4 million generated from our operating activities, partially offset by cash outflows related to acquisitions of $65.0 million, dividend payments of $14.1 million made to our shareholders during the first half of fiscal year 2018, as well as capital expenditures of $5.7 million.
Cash flows provided by operating activities were $23.4 million during the six months ended March 31, 2018, comprised primarily of earnings of $57.6 million, including net income of $83.5 million and the impact of non-cash related charges of $25.9 million.
Cash flows provided by operating activities were $43.3 million during the six months ended March 31, 2017 and comprised primarily of earnings of $42.2 million, including net income of $14.0 million and the impact of non-cash related charges of $14.3 million.
Cash used in investing activities of $10.7 million during the six months ended March 31, 2017 included a cash payment of $5.3 million for the acquisition of CoolLab and $5.2 million of capital expenditures.
During the six months ended March 31, 2018, we made principal payments of $0.5 million under the term loan.
During the six months ended March 31, 2018, we incurred cash interest expense of $4.0 million on the term loan.


item3.txt
Most of these transactions or balances are denominated in Euros, British Pounds and a variety of Asian currencies.
Sales in currencies other than the U.S. dollar were approximately 29% and 38% of our total sales, respectively, during the six months ended March 31, 2018 and 2017.
Such balances were approximately $150.5 million and $51.6 million, respectively, at March 31, 2018 and September 30, 2017, and related to the Euro, British Pound and a variety of Asian currencies.
We incurred foreign currency losses of $2.5 million and $1.0 million, respectively, during the six months ended March 31, 2018 and 2017, which related to the currency fluctuation on these balances between the time the transaction occurred and the ultimate settlement of the transaction.


part2.txt
The timing and amount of any shares repurchased are based on market and business conditions, legal requirements and other factors and may be commenced or suspended at any time at our discretion.
There were no shares repurchased under this program during the six months ended March 31, 2018.


